Immunohistochemical staining seems mandatory for individualizing and shortening follow-up in unilateral primary aldosteronism.
CYP11B2
adrenal adenoma
adrenal venous sampling
antibodies
histopathology
immunohistochemistry
primary aldosteronism
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
12
07
2023
received:
10
11
2022
accepted:
24
07
2023
pubmed:
1
8
2023
medline:
1
8
2023
entrez:
1
8
2023
Statut:
ppublish
Résumé
The clinical significance of immunohistochemistry (IHC) for unilateral primary aldosteronism (PA) has been unclear. Individualized follow-up of PA patients could be in sight. Long-term outcomes of patients, classified based on IHC, need further investigation. We aimed to assess long-term clinical outcomes for unilateral PA, classifying patients based on IHC. A nationwide observational study, with up to 16 years follow-up, executed in 2007-2016 at Landspitali University Hospital, tertiary referral center. Patients were diagnosed and treated in line with the current guidelines. Haematoxylin and eosin (H&E) tissue slides were stained using CYP11B1 and -B2 antibodies. All cases were re-evaluated and classified according to the HISTALDO consensus. Outcomes were assessed using the PASO criteria. All unilateral PA patients diagnosed in 2007-2016 in Iceland, 26 patients aged 28-73 years, who underwent adrenalectomy, were included. Aldosterone, renin, and cortisol values, use and dosage of antihypertensives, potassium supplementation, blood pressure and serum potassium pre-intervention and throughout follow-up, and histopathology results post-adrenalectomy. Following IHC, an aldosterone-producing nodule was seen in 12 adrenals, an aldosterone-producing adenoma in 10 and multiple aldosterone-producing micronodules in four. IHC altered histopathology from previous H&E diagnosis in 23% (6/26) of the patients. In total, 81% (21/26) of the patients had partial clinical success. Eight percent (2/26) of the patients needed potassium supplementation during follow-up. In the classical group, the AVS results were more determinative with significantly higher lateralization index (median 10.1 vs. 5.3, p = .04) and more contralateral suppression (median nondominant ratio 0.4 vs. 1.0, p = .03). One out of five patients with complete clinical success at 12 months post-op had severe relapse later, the other four were normotensive without antihypertensives for up to 10 years. We found IHC mandatory for accurate histopathologic diagnosis of PA. Our results support the importance of contralateral suppression when interpreting AVS results. Also, the study highlights the complicated assessment of clinical outcome and importance of aldosterone and renin measurements during follow-up.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
441-448Subventions
Organisme : Landspitali Research Fund
ID : B-2020-008
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. JACC. 2005;45(8):1243-1248. doi:10.1016/j.jacc.2005.01.015
Monticone S, D'Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diab Endocrinol. 2018;6(1):41-50. doi:10.1016/s2213-8587(17)30319-4
Stewart PM. Mineralocorticoid hypertension. The Lancet. 1999;353(9161):1341-1347. doi:10.1016/S0140-6736(98)06102-9
White ML, Gauger PG, Doherty GM, et al. The role of radiologic studies in the evaluation and management of primary hyperaldosteronism. Surgery. 2008;144(6):926-933. doi:10.1016/j.surg.2008.07.025
Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136(6):1227-1235. doi:10.1016/j.surg.2004.06.051
Abe T, Naruse M, Young Jr. WF, et al. A novel CYP11B2-specific imaging agent for detection of unilateral subtypes of primary aldosteronism. J Clin Endocrinol Metab. 2016;101(3):1008-1015. doi:10.1210/jc.2015-3431
Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061
Nishimoto K, Nakagawa K, Li D, et al. Adrenocortical zonation in humans under normal and pathological conditions. The J Clin Endocrinol Metab. 2010;95(5):2296-2305. doi:10.1210/jc.2009-2010
Gomez-Sanchez CE, Qi X, Velarde-Miranda C, et al. Development of monoclonal antibodies against human CYP11B1 and CYP11B2. Mol Cell Endocrinol. 2014;383(1-2):111-117. doi:10.1016/j.mce.2013.11.022
Enberg U, Volpe C, Hoog A, et al. Postoperative differentiation between unilateral adrenal adenoma and bilateral adrenal hyperplasia in primary aldosteronism by mRNA expression of the gene CYP11B2. Eur J Endocrinol. 2004;151(1):73-85.
Volpe C, Hamberger B, Höög A, et al. Primary aldosteronism: functional histopathology and long-term follow-up after unilateral adrenalectomy. Clin Endocrinol. 2015;82(5):639-647. doi:10.1111/cen.12645
Omura M, Sasano H, Fujiwara T, Yamaguchi K, Nishikawa T. Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. Metabolism. 2002;51(3):350-355. doi:10.1053/meta.2002.30498
Nanba K, Tsuiki M, Sawai K, et al. Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry. J Clin Endocrinol Metab. 2013;98(4):1567-1574. doi:10.1210/jc.2012-3726
Williams TA, Gomez-Sanchez CE, Rainey WE, et al. International histopathology consensus for unilateral primary aldosteronism. J Clin Endocrinol Metab. 2021;106(1):42-54. doi:10.1210/clinem/dgaa484
Volpe C, Hamberger B, Zedenius J, Juhlin CC. Impact of immunohistochemistry on the diagnosis and management of primary aldosteronism: an important tool for improved patient follow-up. Scand J Surg. 2020;109(2):133-142. doi:10.1177/1457496918822622
Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diab Endocrinol. 2017;5(9):689-699. doi:10.1016/s2213-8587(17)30135-3
Sigurjonsdottir HA, Gronowitz M, Andersson O, et al. Unilateral adrenal hyperplasia is a usual cause of primary hyperaldosteronism. results from a Swedish screening study. BMC Endocr Disord. 2012;12:17. doi:10.1186/1472-6823-12-17
Jakobsson H, Farmaki K, Sakinis A, Ehn O, Johannsson G, Ragnarsson O. Adrenal venous sampling: the learning curve of a single interventionalist with 282 consecutive procedures. Diagn Interv Radiol. 2018;24(2):89-93. doi:10.5152/dir.2018.17397
Gunnarsdottir H, Jonsdottir G, Birgisson G, Gudmundsson J, Sigurjonsdottir HA. Are we only detecting the tip of the iceberg? A nationwide study on primary aldosteronism with up to 8-Year follow-up. Endocr Res. 2022;47(3-4):104-112. doi:10.1080/07435800.2022.2068572
Ito A, Yamazaki Y, Sasano H, et al. A case of primary aldosteronism caused by unilateral multiple adrenocortical micronodules presenting as muscle cramps at rest: the importance of functional histopathology for identifying a culprit lesion. Pathol Int. 2017;67(4):214-221. doi:10.1111/pin.12521
Volpe C, Höög A, Ogishima T, et al. Immunohistochemistry improves histopathologic diagnosis in primary aldosteronism. J Clin Pathol. 2013;66(4):351-354. doi:10.1136/jclinpath-2012-201287
Wang H, Wang F, Zhang Y, et al. Surgical outcomes of aldosterone-producing adenoma on the basis of the histopathological findings. Front Endocrinol. 2021;12:663096. doi:10.3389/fendo.2021.663096
Meyer LS, Handgriff L, Lim JS, et al. Single-center prospective cohort study on the histopathology, genotype, and postsurgical outcomes of patients with primary aldosteronism. Hypertension. 2021;78(3):738-746. doi:10.1161/hypertensionaha.121.17348
Umakoshi H, Tanase-Nakao K, Wada N, et al. Importance of contralateral aldosterone suppression during adrenal vein sampling in the subtype evaluation of primary aldosteronism. Clin Endocrinol. 2015;83(4):462-467. doi:10.1111/cen.12761
Reincke M, Williams TA. True unilateral primary aldosteronism exists, and unilateral adrenalectomy saves lives. Eur J Endocrinol. 2022;186(6):C5-C7. doi:10.1530/eje-22-0123
Rossi GP, Cesari M, Cuspidi C, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013;62(1):62-69. doi:10.1161/HYPERTENSIONAHA.113.01316
Libianto R, Russell GM, Stowasser M, et al. Detecting primary aldosteronism in Australian primary care: a prospective study. Med J Aust. 2022;216(8):408-412. doi:10.5694/mja2.51438
Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol. 1999;48(5):756-760. doi:10.1046/j.1365-2125.1999.00070.x
Grytaas M, Strømsøy S, Rørvik J, et al. Clinical characteristics and long-term outcome of primary aldosteronism in a Norwegian population. Horm Metab Res. 2017;49(11):838-846. doi:10.1055/s-0043-118909
Ip JCY, Pang TCY, Pon CK, et al. Mutations in KCNJ5 determines presentation and likelihood of cure in primary hyperaldosteronism. ANZ J Surg. 2015;85(4):279-283. doi:10.1111/ans.12470